cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Biogen Inc
66 own
58 watching
Current Price
$185.76
$3.46
(1.9%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
29,834.42M
52-Week High
52-Week High
269.42999
52-Week Low
52-Week Low
181.31000
Average Volume
Average Volume
0.94M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
26.7899
iconMarket Capitalization29,834.42M
icon52-Week High269.42999
icon52-Week Low181.31000
iconAverage Volume0.94M
iconDividend Yield--
iconP/E Ratio26.7899
What does the Biogen Inc do?
Biogen Inc., a biopharmaceutical company, discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies. The company's Phase III clinical trial products comprise GAZYVA for the treatment of front-line indolent non-hodgkin's lymphoma; and Aducanumab and E2609 for Alzheimer's disease. Its Phase II clinical trial products include BIIB074 for trigeminal neuralgia, lumbosacral radiculopathy, and erythromelalgia; BAN2401 for Alzheimer's disease; Opicinumab (anti-LINGO-1) for MS; TYSABRI for acute ischemic stroke; rAAV-XLRS for X-linked juvenile retinoschisis; BG00011 (STX-100) for idiopathic pulmonary fibrosis; and Dapirolizumab pegol and BIIB059 (Anti-BDCA02) for lupus. The company's Phase I clinical trial products comprise BIIB061 for MS; BIIB054 for Parkinson's disease; BIIB067 (IONIS-SOD1Rx) for amyotrophic lateral sclerosis; and BIIB068 (BTK Inhibitor) for autoimmune disease. It has collaboration agreements with AbbVie, Inc.; Acorda Therapeutics, Inc.; Applied Genetic Technologies Corporation; Eisai Co., Ltd.; Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and University of Pennsylvania. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Biogen Inc make?
News & Events about Biogen Inc.
Ticker Report
1 year ago
Biogen Inc. (NASDAQ:BIIB Get Rating) EVP Ginger Gregory sold 2,681 shares of the firms stock in a transaction dated Friday, April 28th. The shares were sold at an average price of $300.00, for a total transaction of $804,300.00. Following the transaction, the executive vice president ...
Zolmax
1 year ago
Biogen Inc. (NASDAQ:BIIB Get Rating) Equities researchers at Jefferies Financial Group reduced their Q3 2023 earnings per share estimates for Biogen in a note issued to investors on Tuesday, April 25th. Jefferies Financial Group analyst M. Yee now anticipates that the biotechnology company will earn...
Business Wire
1 year ago
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter ended March 31, 2023. The following information represents select highlights from the full UK annual report...
Fool.com Headlines
1 year ago
One is slightly cheaper than the other.When you think of biotech investing, you might focus on small companies that are years away from product revenue. They may eventually offer great rewards -- but at the moment, risk is high. If you're more of a cautious investor, that may not be your thing. That...
Frequently Asked Questions
Frequently Asked Questions
What is Biogen Inc share price today?
plus_minus_icon
Can Indians buy Biogen Inc shares?
plus_minus_icon
How can I buy Biogen Inc shares from India?
plus_minus_icon
Can Fractional shares of Biogen Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Biogen Inc stocks?
plus_minus_icon
What is today’s traded volume of Biogen Inc?
plus_minus_icon
What is today’s market capitalisation of Biogen Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Biogen Inc?
plus_minus_icon
What percentage is Biogen Inc down from its 52-Week High?
plus_minus_icon
What percentage is Biogen Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$185.76
$3.46
(1.9%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$38.06
$0.26 (0.69 %)
LyondellBasell Industries N.V.
LyondellBasell Industries N.V.
$94.28
$0.18 (0.19 %)
HP Inc.
HP Inc.
$36.58
$0.58 (1.61 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$468.01
$9.07 (1.98 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$38.06
$0.26 (0.69 %)
LyondellBasell Industries N.V.
LyondellBasell Industries N.V.
$94.28
$0.18 (0.19 %)
HP Inc.
HP Inc.
$36.58
$0.58 (1.61 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$468.01
$9.07 (1.98 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00